The 21st BioEquity Europe: Digital
European innovators helped pave the way for the world’s first COVID-19 vaccines. What’s coming next from Europe’s academic and biotech leaders?
Doing the Right Right Thing, and Doing it Better: A Life Sciences Primer on ESG
To be credible and investible, ESG is becoming critical to the fund manager’s perspective, as investors shift further to sustainable investment.
Heart Failure Awareness – why should we care?
February is Heart Awareness Month. In this Insight, Karin Kleinhans of LSP discusses how heart failure, one of the leading causes of death worldwide, is a global problem that demands urgent attention.
BioWorld Article by Mike Ward on Medicxi’s launch of Centessa Pharmaceuticals
Francesco de Rubertis, a co-founder of Medicixi Ventures, has unveiled the next generation of the venture-backed asset-centric biopharma model with the creation of Centessa Pharmaceuticals Ltd. The new company was created by acquiring, in all-share transactions, total control of 10 companies from the Medicxi portfolio. Read more at BioWorld.com
Destiny Pharma’s Call to Arms to Combat AMR
CEO Neil Clark and CSO Dr Bill Love from Europe’s leading anti-infectives biotech company Destiny Pharma, on how the makers and influencers of health policy could fuel a renaissance in drug development…
